{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:09:09Z","timestamp":1792598949219,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30 EY002162"],"award-info":[{"award-number":["P30 EY002162"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ophtha.2021.04.024","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T02:12:52Z","timestamp":1619575972000},"page":"1627-1651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Teprotumumab"],"prefix":"10.1016","volume":"128","author":[{"given":"Bryan J.","family":"Winn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2021.04.024_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0026-0495(72)90041-8","article-title":"Epidemiologic aspects of Hashimoto\u2019s thyroiditis and Graves\u2019 disease in Rochester, Minnesota (1935\u20131967), with special reference to temporal trends","volume":"21","author":"Furszyfer","year":"1972","journal-title":"Metabolism"},{"key":"10.1016\/j.ophtha.2021.04.024_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1977.tb01340.x","article-title":"The spectrum of thyroid disease in a community: the Whickham survey","volume":"7","author":"Tunbridge","year":"1977","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2011.10.005","article-title":"Epidemiology of Graves\u2019 orbitopathy (GO) and relationship with thyroid disease","volume":"26","author":"Lazarus","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","article-title":"The incidence of Graves\u2019 ophthalmopathy in Olmsted County, Minnesota","volume":"120","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","article-title":"Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort","volume":"121","author":"Bartley","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease: emerging paradigms","volume":"55","author":"Naik","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamacardio.2019.4032","article-title":"Association of cardiac rehabilitation with decreased hospitalization and mortality risk after cardiac valve surgery","volume":"4","author":"Patel","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib9","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"key":"10.1016\/j.ophtha.2021.04.024_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2013.0240","article-title":"Spontaneous improvement of untreated mild Graves\u2019 ophthalmopathy: Rundle\u2019s curve revisited","volume":"24","author":"Menconi","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2021.04.024_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/thy.1998.8.423","article-title":"Natural history of thyroid eye disease","volume":"8","author":"Perros","year":"1998","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2021.04.024_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/bmj.1.6056.273","article-title":"Occasional review. Ophthalmic Graves\u2019s disease: natural history and detailed thyroid function studies","author":"Teng","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.ophtha.2021.04.024_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib16","first-page":"249125","article-title":"Graves\u2019 ophthalmopathy: VISA versus EUGOGO classification, assessment, and management","volume":"2015","author":"Barrio-Barrio","year":"2015","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/thy.1992.2.229","article-title":"Immunosuppressive treatment of Graves\u2019 ophthalmopathy","volume":"2","author":"Wiersinga","year":"1992","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2021.04.024_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/01676839609150235","article-title":"Advances in medical therapy of thyroid-associated ophthalmopathy","volume":"15","author":"Wiersinga","year":"1996","journal-title":"Orbit"},{"key":"10.1016\/j.ophtha.2021.04.024_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ophtha.2006.08.026","article-title":"Thyroid orbitopathy","volume":"114","author":"Nunery","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib20","first-page":"73","article-title":"Ophthalmic Graves\u2019 disease: a dual theory of pathogenesis","volume":"4","author":"Nunery","year":"1991","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.ophtha.2021.04.024_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002341-199306000-00001","article-title":"The association of cigarette smoking with clinical subtypes of ophthalmic Graves\u02bc disease","volume":"9","author":"Nunery","year":"1993","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib22","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of thyroid eye disease","volume":"34","author":"Uddin","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/IOP.0000000000001550","article-title":"Re: \u201cNoninflammatory thyroid eye disease","volume":"36","author":"Rubinstein","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ophtha.2010.04.004","article-title":"Do subtypes of Graves\u2019 orbitopathy exist?","volume":"118","author":"Regensburg","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib25","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib26","first-page":"205","article-title":"Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease","volume":"27","author":"Zoumalan","year":"2007","journal-title":"J\u00a0Neuro-Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib27","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.18240\/ijo.2019.07.20","article-title":"Intravenous glucocorticoids therapy in the treatment of Graves\u2019 ophthalmopathy: a systematic review and metaanalysis","volume":"12","author":"Zhao","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy","volume":"61","author":"Aktaran","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ophtha.2021.04.024_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib32","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib33","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","article-title":"A\u00a0prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy","volume":"108","author":"Gorman","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/jc.2003-031769","article-title":"Editorial: orbital radiotherapy for Graves\u2019 ophthalmopathy","volume":"89","author":"Bartalena","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib36","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00066-015-0848-9","article-title":"Study of the anti-inflammatory effects of low-dose radiation: the contribution of biphasic regulation of the antioxidative system in endothelial cells","volume":"191","author":"Large","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/cei.12344","article-title":"Low and moderate doses of ionizing radiation up to 2 Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function","volume":"179","author":"Wunderlich","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A\u00a0randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy","volume":"89","author":"Prummel","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":"Randomised double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2021.04.024_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF03347943","article-title":"Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study","volume":"14","author":"Marcocci","year":"1991","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ophtha.2021.04.024_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","article-title":"Rituximab for thyroid eye disease","volume":"26","author":"Silkiss","year":"2010","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib45","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib46","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-16-0552","article-title":"Management of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy\u2014lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/07435800.2011.635622","article-title":"CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves\u2019 orbitopathy and correlate with disease activity","volume":"37","author":"Slowik","year":"2012","journal-title":"Endocr Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/thy.2009.0278","article-title":"A\u00a0stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts","volume":"20","author":"Kumar","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2021.04.024_bib50","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib52","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1097\/IOP.0000000000001346","article-title":"Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery","volume":"35","author":"Copperman","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib53","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ICU.0000000000000402","article-title":"Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease","volume":"28","author":"Strianese","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","article-title":"Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy","volume":"24","author":"Durrani","year":"2005","journal-title":"Orbit"},{"key":"10.1016\/j.ophtha.2021.04.024_bib57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/bmj.3.5871.72","article-title":"Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity","volume":"3","author":"Kendall-Taylor","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.ophtha.2021.04.024_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2008-0044","article-title":"Thyrotropin and homologous glycoprotein hormone receptors: structural and functional aspects of extracellular signaling mechanisms","volume":"30","author":"Kleinau","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ophtha.2021.04.024_bib59","doi-asserted-by":"crossref","first-page":"15462","DOI":"10.1073\/pnas.242328999","article-title":"Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland","volume":"99","author":"Postiglione","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.04.024_bib60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2021.04.024_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/105072502753600124","article-title":"Thyrotropin receptor expression in orbital adipose\/connective tissues from patients with thyroid-associated ophthalmopathy","volume":"12","author":"Bahn","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2021.04.024_bib62","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib63","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2021.04.024_bib64","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/JME-17-0276","article-title":"IGF1 receptor and thyroid-associated ophthalmopathy","volume":"61","author":"Mohyi","year":"2018","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib65","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"key":"10.1016\/j.ophtha.2021.04.024_bib66","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib67","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib68","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy","volume":"42","author":"Marin\u00f2","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.ophtha.2021.04.024_bib69","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1210\/endo-119-2-940","article-title":"Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves\u2019-IgG","volume":"119","author":"Tramontano","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib70","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/14728222.2017.1288215","article-title":"TSHR as a therapeutic target in Graves\u2019 disease","volume":"21","author":"Smith","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ophtha.2021.04.024_bib71","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1210\/jc.2014-3566","article-title":"Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves\u2019 disease immunoglobins","volume":"100","author":"Krieger","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib72","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib73","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2013-1149","article-title":"A\u00a0small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy","volume":"98","author":"Turcu","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib74","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1172\/JCI114768","article-title":"Thyroid-stimulating antibody activity between different immunoglobulin G subclasses","volume":"86","author":"Weetman","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2021.04.024_bib75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0029-1220913","article-title":"TSH receptor\u2014autoantibody interactions","volume":"41","author":"Rees Smith","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib76","first-page":"167","article-title":"Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib77","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib78","doi-asserted-by":"crossref","first-page":"22910","DOI":"10.1074\/jbc.M703597200","article-title":"Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma","volume":"282","author":"Hong","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ophtha.2021.04.024_bib79","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.94.12.6307","article-title":"The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ","volume":"94","author":"Chesney","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.04.024_bib80","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biocel.2003.10.005","article-title":"Circulating fibrocytes: collagen-secreting cells of the peripheral blood","volume":"36","author":"Quan","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib81","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ophtha.2021.04.024_bib82","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1073\/pnas.73.12.4379","article-title":"Amino-terminal sequences of two polypeptides from human serum with nonsuppressible insulin-like and cell-growth-promoting activities: evidence for structural homology with insulin B chain","volume":"73","author":"Rinderknecht","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.04.024_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fendo.2018.00117","article-title":"IGF-binding proteins: why do they exist and why are there so many?","volume":"9","author":"Allard","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib84","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/dneu.20778","article-title":"Toward a comprehensive neurobiology of IGF-I","volume":"70","author":"Torres-Aleman","year":"2010","journal-title":"Dev Neurobiol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib85","series-title":"UpToDate","article-title":"Physiology of insulin-like growth factor 1.","author":"Clemmons","year":"2020"},{"key":"10.1016\/j.ophtha.2021.04.024_bib86","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1210\/en.2011-0231","article-title":"Minireview: IGF, insulin, and cancer","volume":"152","author":"Gallagher","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1096-6374(03)00038-8","article-title":"Serum levels of insulin-like growth factor I and its binding proteins in health and disease","volume":"13","author":"Juul","year":"2003","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-13-0661","article-title":"Serum levels of bioactive IGF1 and physiological markers of ageing in healthy adults","volume":"170","author":"Vestergaard","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pneurobio.2009.07.008","article-title":"Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan","volume":"89","author":"Aleman","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib90","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1210\/jcem.84.2.5455","article-title":"Insulin-like growth factor-I and cognitive function in healthy older men","volume":"84","author":"Aleman","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib91","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/gerona\/gly144","article-title":"IGF-1 deficiency promotes pathological remodeling of cerebral arteries: a potential mechanism contributing to the pathogenesis of intracerebral hemorrhages in aging","volume":"74","author":"Fulop","year":"2019","journal-title":"J\u00a0Gerontol A Bio Sci Med Sci"},{"key":"10.1016\/j.ophtha.2021.04.024_bib92","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/MOO.0000000000000652","article-title":"Insulin-like growth factor 1: role in the auditory system and therapeutic potential in otology","volume":"28","author":"Gao","year":"2020","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.1089169","article-title":"Healthy animals with extreme longevity","volume":"302","author":"Arantes-Oliveira","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2021.04.024_bib94","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib95","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1073\/pnas.0807025106","article-title":"Resistance to age-dependent thymic atrophy in long-lived mice that are deficient in pregnancy-associated plasma protein A","volume":"106","author":"Vallejo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.04.024_bib96","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/gerona\/61.10.1019","article-title":"Genetic modulation of hormone levels and life span in hybrids between laboratory and wild-derived mice","volume":"61","author":"Harper","year":"2006","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ophtha.2021.04.024_bib97","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1073\/pnas.0705467105","article-title":"Functionally significant insulin-like growth factor I receptor mutations in centenarians","volume":"105","author":"Suh","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2021.04.024_bib98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/joe.0.1470203","article-title":"Type I insulin-like growth factor receptor expression in different developmental stages of human thymocytes","volume":"147","author":"Kooijman","year":"1995","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib99","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-3083.2002.01077.x","article-title":"The thymus gland: a target organ for growth hormone","volume":"55","author":"Savino","year":"2002","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib100","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V80.5.1207.1207","article-title":"Insulin-like growth factor-I regulates pro-B cell differentiation","volume":"80","author":"Landreth","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ophtha.2021.04.024_bib101","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.152.9.4320","article-title":"In\u00a0vivo administration of insulin-like growth factor-I stimulates primary B lymphopoiesis and enhances lymphocyte recovery after bone marrow transplantation","volume":"152","author":"Jardieu","year":"1994","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib102","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1172\/JCI116621","article-title":"Insulin-like growth factor-1 stimulation of lymphopoiesis","volume":"92","author":"Clark","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2021.04.024_bib103","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/41.3.352","article-title":"Inappropriate serum levels of IGF-I and IGFBP-3 in patients with rheumatoid arthritis","volume":"41","author":"Matsumoto","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib104","first-page":"81","article-title":"Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis","volume":"19","author":"Neidel","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2015.04.002","article-title":"The pathogenesis of systemic sclerosis","volume":"41","author":"Stern","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl","key":"10.1016\/j.ophtha.2021.04.024_bib106","first-page":"751","article-title":"Interstitial fibrosis and growth factors","volume":"108","author":"Lasky","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.ophtha.2021.04.024_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/rccm.2201012","article-title":"Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome","volume":"167","author":"Krein","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14814\/phy2.12197","article-title":"Enhanced production of IGF-I in the lungs of fibroproliferative ARDS patients","volume":"2","author":"Andonegui","year":"2014","journal-title":"Physiol Rep"},{"key":"10.1016\/j.ophtha.2021.04.024_bib109","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1164\/rccm.200802-228OC","article-title":"Insulin-Like growth factor-i receptor blockade improves outcome in mouse model of lung injury","volume":"179","author":"Choi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04561-4","article-title":"IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model","volume":"7","author":"Pi\u00f1eiro-Hermida","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2021.04.024_bib111","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3389\/fmicb.2019.02541","article-title":"Insulin-like growth factor 1 regulates acute inflammatory lung injury mediated by influenza virus infection","volume":"10","author":"Li","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib112","doi-asserted-by":"crossref","first-page":"110167","DOI":"10.1016\/j.mehy.2020.110167","article-title":"Is there a role for insulin-like growth factor inhibition in the treatment of COVID-19-related adult respiratory distress syndrome?","volume":"144","author":"Winn","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.ophtha.2021.04.024_bib113","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib114","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12885-016-2437-4","article-title":"Insulin-like growth factor-1 signaling in renal cell carcinoma","volume":"16","author":"Tracz","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ophtha.2021.04.024_bib115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-149-7-200810070-00006","article-title":"Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies","volume":"149","author":"Roddam","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib116","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1470-2045(10)70095-4","article-title":"Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies","volume":"11","author":"Key","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib117","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/ijc.24927","article-title":"Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies","volume":"126","author":"Rinaldi","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ophtha.2021.04.024_bib118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2010.171","article-title":"Growth hormone, the insulin-like growth factor axis, insulin and cancer risk","volume":"7","author":"Clayton","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib119","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10911-008-9099-z","article-title":"IGF and insulin receptor signaling in breast cancer","volume":"13","author":"Belfiore","year":"2008","journal-title":"J\u00a0Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.ophtha.2021.04.024_bib120","first-page":"257058","article-title":"Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer","volume":"2010","author":"Beauchamp","year":"2010","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib121","first-page":"445","article-title":"Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma","volume":"179","author":"Chuang","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib122","first-page":"1","article-title":"IGF-I mediated survival pathways in normal and malignant cells","volume":"1766","author":"Kurmasheva","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ophtha.2021.04.024_bib123","doi-asserted-by":"crossref","first-page":"29501","DOI":"10.18632\/oncotarget.15704","article-title":"Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy","volume":"8","author":"Qu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ophtha.2021.04.024_bib124","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.mrrev.2016.09.005","article-title":"Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer","volume":"772","author":"Philippou","year":"2017","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib126","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib127","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib128","first-page":"276","article-title":"SAT-432 pharmacokinetics (PK) and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) blocking antibody, in active thyroid eye disease (TED)","volume":"4","author":"Xin","year":"2020","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.ophtha.2021.04.024_bib129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2021.04.024_bib131","author":"Fidler"},{"key":"10.1016\/j.ophtha.2021.04.024_bib134","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib135","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for research through Collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib136","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2011.36.6799","article-title":"Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer","volume":"29","author":"Ramalingam","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib138","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-09-3220","article-title":"A\u00a0phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors","volume":"16","author":"Kurzrock","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib139","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/1078-0432.CCR-10-1731","article-title":"Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors","volume":"17","author":"Bagatell","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib143","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves\u2019 ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ophtha.2021.04.024_bib144","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib146","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2021.04.024_bib149","first-page":"1","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"i","author":"Jain","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib150","series-title":"American Academy of Ophthalmology","article-title":"Long-term assessment of proptosis and diplopia from the OPTIC trial of teprotumumab in thyroid eye disease. In:","author":"Douglas","year":"2020"},{"key":"10.1016\/j.ophtha.2021.04.024_bib152","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with targeted oncologic treatment: mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ophtha.2021.04.024_bib153","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.mlg.0000200791.77819.eb","article-title":"Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel","volume":"116","author":"Iwai","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ophtha.2021.04.024_bib154","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MAO.0000000000001276","article-title":"Activation of IGF1 signaling in the cochlea induces the transcription of its mediators during the protection of cochlear hair cells against aminoglycoside","volume":"38","author":"Hayashi","year":"2017","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib155","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/WNR.0b013e328311ca4b","article-title":"Insulin-like growth factor I treatment via hydrogels rescues cochlear hair cells from ischemic injury","volume":"19","author":"Fujiwara","year":"2008","journal-title":"Neuroreport"},{"key":"10.1016\/j.ophtha.2021.04.024_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04526-7","article-title":"Insulin-like growth factor 1 in relation to future hearing impairment: findings from the English Longitudinal Study of Ageing","volume":"7","author":"Lassale","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2021.04.024_bib157","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1741-7015-8-76","article-title":"Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial","volume":"8","author":"Nakagawa","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0219-x","article-title":"A\u00a0randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment","volume":"12","author":"Nakagawa","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib159","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12020-011-9515-9","article-title":"Evaluation of hearing loss in patients with Graves\u2019 disease","volume":"41","author":"Berker","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ophtha.2021.04.024_bib160","first-page":"109","article-title":"The prevalence of hearing loss in patients with autoimmune thyroid disease: a prospective study","volume":"52","author":"Mahafzah","year":"2018","journal-title":"Jordan Med J"},{"key":"10.1016\/j.ophtha.2021.04.024_bib161","doi-asserted-by":"crossref","first-page":"651","DOI":"10.14310\/horm.2002.1577","article-title":"IGF1 deficiency in newly diagnosed Graves\u2019 disease patients","volume":"14","author":"Martin","year":"2015","journal-title":"Hormones"},{"key":"10.1016\/j.ophtha.2021.04.024_bib162","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.tem.2013.03.004","article-title":"The therapeutic potential of IGF-I in skeletal muscle repair","volume":"24","author":"Song","year":"2013","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ophtha.2021.04.024_bib163","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-1-4","article-title":"Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: insights from genetic models","volume":"1","author":"Schiaffino","year":"2011","journal-title":"Skelet Muscle"},{"key":"10.1016\/j.ophtha.2021.04.024_bib164","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nutres.2019.05.006","article-title":"Low serum levels of insulin-like growth factor-1 are associated with an increased risk of rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"Yang","year":"2019","journal-title":"Nutr Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib165","first-page":"9","article-title":"The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease","volume":"64","author":"Eivindson","year":"2005","journal-title":"Horm Res"},{"key":"10.1016\/j.ophtha.2021.04.024_bib166","first-page":"228","article-title":"The insulin-like growth factor axis in children with inflammatory bowel disease","volume":"36","author":"Corkins","year":"2003","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.ophtha.2021.04.024_bib167","first-page":"832","article-title":"Insulin-like growth factor system in remission and flare of inflammatory bowel diseases","volume":"127","author":"Krakowska-Stasiak","year":"2017","journal-title":"Polish Arch Intern Med"},{"key":"10.1016\/j.ophtha.2021.04.024_bib168","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3899\/jrheum.150280","article-title":"Insulin-like growth factor 1 and adiponectin and associations with muscle deficits, disease characteristics, and treatments in rheumatoid arthritis","volume":"42","author":"Baker","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib169","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ajpath.2015.05.020","article-title":"Insulin-like growth factor-1 contributes to mucosal repair by \u03b2-arrestin2\u2013mediated extracellular signal-related kinase signaling in experimental colitis","volume":"185","author":"Chen","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib170","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/00054725-200411000-00021","article-title":"Growth factors in inflammatory bowel disease","volume":"10","author":"Theiss","year":"2004","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.ophtha.2021.04.024_bib171","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.cgh.2020.09.054","article-title":"Familial risk of inflammatory bowel disease\u2014a population-based cohort study in South Korea","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ophtha.2021.04.024_bib172","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/IOP.0000000000001943","article-title":"New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy","volume":"37","author":"Ashraf","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib173","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.ajoc.2020.100744","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Reports"},{"key":"10.1016\/j.ophtha.2021.04.024_bib175","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/IOP.0000000000001087","article-title":"Noninflammatory thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2021.04.024_bib176","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/IOP.0000000000001551","article-title":"Reply re: \u201cNoninflammatory thyroid eye disease","volume":"36","author":"Ugradar","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3S","key":"10.1016\/j.ophtha.2021.04.024_bib177","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1097\/IOP.0000000000001831","article-title":"Teprotumumab for dysthyroid optic neuropathy","volume":"37","author":"Sears","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.ophtha.2021.04.024_bib178","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2020.5296","article-title":"Teprotumumab for optic neuropathy in thyroid eye disease","volume":"139","author":"Slentz","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib179","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2021.04.024_bib180","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","author":"Jain","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2021.04.024_bib181","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ajo.2019.07.021","article-title":"A\u00a0new era in the treatment of thyroid eye disease","volume":"208","author":"Patel","year":"2019","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021003183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021003183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:12:36Z","timestamp":1758982356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":168,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0161642021003183"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.024","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teprotumumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}